Sanofi SA
featured
A dispute within the FDA on whether to put new lung-cancer warnings on ARBs taken by millions of people is unlikely to have any significant effect on the manufacturers stocks.
» Read More
More
-
NEW YORK, June 17- ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
-
NEW YORK, June 17- ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
-
NEW YORK-- French drugmaker Sanofi said Monday the Food and Drug Administration approved a new version of its flu vaccine Fluzone that is designed to prevent four types of the virus.
-
June 10- French drugmaker Sanofi SA said the U.S. Food and Drug Administration had approved its four-strain influenza vaccine, which is meant to provide better protection from infection than traditional three-strain flu vaccines.
-
LONDON, June 10- Bank of America Merrill Lynch scooped the prize as top pan-European equity brokerage at the annual Thomson Reuters Extel Awards on Monday, ending UBS's 12- year winning streak. Voters picked Bank of America Merrill Lynch as leading pan-European broker in equity and equity-linked research, relegating Swiss-based UBS to second place.
-
LONDON, June 10- One of the world's longest running drug development sagas may draw to a close this month as French firm Sanofi hopes for a European green light for its new multiple sclerosis medicine Lemtrada.
-
Royalty Pharma raised its hostile bid for Irish drug firm Elan to a potential $8 billion on Friday, coming back for the third time after just 7.5 percent of shareholders accepted the last offer.
-
DUBLIN, June 7- Royalty Pharma raised its hostile bid for Irish drug firm Elan to a potential $8 billion on Friday, after just 7.5 percent of the target company's shareholders accepted its previous offer.
-
*Key data on new Sanofi products at ADA meeting this month. FRANKFURT, June 7- In a leafy suburb of Frankfurt, a state-of-the-art plant churns out up to 1 million insulin pens every day in French drugmaker Sanofi's drive to keep its no. 2 spot in the $43 billion- a-year diabetes market.
-
HERZLIYA, Israel, June 6- Inspired by its success in high-tech electronics and software, Israel is hoping to pull off the same trick in life sciences. High-tech has been one of Israel's main growth engines and companies such as Intel Inc, IBM and Google Inc have major R&D centres in the country.
-
*Sanofi sags after dropping 2 late-stage drugs. PARIS, June 3- European shares dropped early on Monday, with indexes testing technical support levels, mirroring a sell-off in U.S. stocks and after poor Chinese manufacturing data.
-
PARIS, June 3- European shares dropped early on Monday, with a key index hitting a one-month low, mirroring a sell-off in U.S. stocks and after poor Chinese manufacturing data.
-
May 30- Biogen Idec Inc expects a delay in the European launch of its multiple sclerosis drug Tecfidera as the drugmaker works to secure exclusive data that could potentially protect its treatment from generic competition for a longer period.
-
CHICAGO/ LOS ANGELES, May 29- When Smithfield Foods Inc. quietly weaned the first of its pigs off the controversial feed additive ractopamine last year, it may have helped open the door for a Chinese counterpart to acquire the world's largest hog producer.
-
CHICAGO, May 23- Kathrin Jansen is a microbiologist with at least two breakthrough vaccines to her name: she brought the cervical cancer vaccine Gardasil to market for Merck and helped develop the $4 billion a year pneumonia and meningitis vaccine Prevnar 13 for Pfizer.
-
*FDA panel says suvorexant safe, effective at lower doses. On Monday, the FDA's internal reviewers published a report expressing concern about suvorexant's potential to cause next-day sleepiness and impaired driving.
-
NEW YORK, May 22- Little known biotechnology company Merrimack Pharmaceuticals Inc has quietly built a large pipeline of experimental cancer treatments that it aims to deliver at a fraction of the cost spent by larger rivals. Medicare system contending with new cancer treatments that can exceed $100,000 per patient.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.
-
May 21- A new type of asthma drug meant to attack the underlying causes of the respiratory disease slashed episodes by 87 percent in a mid-stage trial, making it a potential game changer for patients with moderate to severe disease, researchers said on Tuesday.
-
May 20- Merck& Co's experimental insomnia drug suvorexant appears generally effective, according to reviewers at the U.S. Food and Drug Administration, but they questioned the company's proposed dosing levels.
Most Popular Video
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.